A S Mansfield1, A J Tafur2,3, C E Wang4, T V Kourelis5,6, E M Wysokinska7, P Yang8. 1. Department of Oncology, Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Mansfield.aaron@mayo.edu. 2. Department of Medicine, Division of Cardiology - Vascular Medicine Program, NorthShore University Health System, Evanston, IL, USA. 3. University of Chicago School of Medicine, Chicago, IL, USA. 4. Department of Surgery, NorthShore University Health System, Evanston, IL, USA. 5. Department of Oncology, Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. 6. Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA. 7. Willmar Regional Cancer Center, Willmar, MN, USA. 8. Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
Abstract
UNLABELLED: Essentials Venous thromboembolism (VTE) prevention strategies require effective risk assessment models. We sought to validate the Khorana Risk Score (KRS) in patients with lung cancer. A high KRS was not predictive of VTE but was independently associated with all-cause mortality. Our findings stress the need for a lung cancer-specific VTE risk assessment model. SUMMARY: Objectives Lung cancer is strongly associated with venous thromboembolism (VTE), but primary prevention against VTE is not a validated management strategy. Risk assessment models will be necessary for efficient implementation of preventative strategies. Materials and methods Utilizing a prospectively collected lung cancer database, we aimed to validate the Khorana Risk Score (KRS) in the prediction of VTE among patients with lung cancer. VTE events were retrospectively identified by reviewers unaware of the clinical prediction score calculation. The association between KRS and the risk of VTE was examined using cumulative incidence function with competing risk models. Mortality prediction was evaluated as a secondary outcome. Results We included 719 patients in our review. The patients were predominantly older men with non-small cell lung cancer and 40% had metastatic disease at inception. The median follow-up was 15.2 months. There were 83 VTEs (11.5%) and 568 (78.8%) patients died. A high KRS (cumulative incidence, 12.4%; 95% confidence interval [CI], 6.4-20.5%) was not associated with VTE compared with an intermediate score (cumulative incidence, 12.1%; 95% confidence interval, 9.5-15.0%) in both univariate and multivariable analyses. However, a high KRS was a predictor of mortality (hazard ratio, 1.7; 95% CI, 1.4-2.2). Conclusions Among patients with lung cancer, the KRS did not stratify the patients at the highest risk of VTE. Improved risk stratification methods are needed for this group of patients prior to implementing a primary prevention strategy.
UNLABELLED: EssentialsVenous thromboembolism (VTE) prevention strategies require effective risk assessment models. We sought to validate the Khorana Risk Score (KRS) in patients with lung cancer. A high KRS was not predictive of VTE but was independently associated with all-cause mortality. Our findings stress the need for a lung cancer-specific VTE risk assessment model. SUMMARY: Objectives Lung cancer is strongly associated with venous thromboembolism (VTE), but primary prevention against VTE is not a validated management strategy. Risk assessment models will be necessary for efficient implementation of preventative strategies. Materials and methods Utilizing a prospectively collected lung cancer database, we aimed to validate the Khorana Risk Score (KRS) in the prediction of VTE among patients with lung cancer. VTE events were retrospectively identified by reviewers unaware of the clinical prediction score calculation. The association between KRS and the risk of VTE was examined using cumulative incidence function with competing risk models. Mortality prediction was evaluated as a secondary outcome. Results We included 719 patients in our review. The patients were predominantly older men with non-small cell lung cancer and 40% had metastatic disease at inception. The median follow-up was 15.2 months. There were 83 VTEs (11.5%) and 568 (78.8%) patients died. A high KRS (cumulative incidence, 12.4%; 95% confidence interval [CI], 6.4-20.5%) was not associated with VTE compared with an intermediate score (cumulative incidence, 12.1%; 95% confidence interval, 9.5-15.0%) in both univariate and multivariable analyses. However, a high KRS was a predictor of mortality (hazard ratio, 1.7; 95% CI, 1.4-2.2). Conclusions Among patients with lung cancer, the KRS did not stratify the patients at the highest risk of VTE. Improved risk stratification methods are needed for this group of patients prior to implementing a primary prevention strategy.
Authors: M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui Journal: J Natl Cancer Inst Date: 2001-07-18 Impact factor: 13.506
Authors: Taxiarchis V Kourelis; Ewa M Wysokinska; Yi Wang; Ping Yang; Aaron S Mansfield; Alfonso J Tafur Journal: Lung Cancer Date: 2014-10-12 Impact factor: 5.705
Authors: Giancarlo Agnelli; Daniel J George; Ajay K Kakkar; William Fisher; Michael R Lassen; Patrick Mismetti; Patrick Mouret; Umesh Chaudhari; Francesca Lawson; Alexander G G Turpie Journal: N Engl J Med Date: 2012-02-16 Impact factor: 91.245
Authors: Davendra P S Sohal; Shiva Shrotriya; Kate Tullio Glass; Robert J Pelley; Michael J McNamara; Bassam Estfan; Marc Shapiro; Jane Wey; Sricharan Chalikonda; Gareth Morris-Stiff; R Matthew Walsh; Alok A Khorana Journal: Cancer Date: 2015-02-11 Impact factor: 6.860
Authors: Nicole M Kuderer; Marek S Poniewierski; Eva Culakova; Gary H Lyman; Alok A Khorana; Ingrid Pabinger; Giancarlo Agnelli; Howard A Liebman; Eric Vicaut; Guy Meyer; Frances A Shepherd Journal: Oncologist Date: 2017-09-26
Authors: J Haltout; A Awada; M Paesmans; M Moreau; J Klastersky; G Machiels; M Ignatiadis; N Kotecki Journal: Support Care Cancer Date: 2019-01-04 Impact factor: 3.603
Authors: Santosh B Murthy; Mary Cushman; Dylan Bobrow; Hooman Kamel; Alexander E Merkler; Mitchell S V Elkind; Lisa M DeAngelis; Babak B Navi Journal: J Clin Neurosci Date: 2018-08-23 Impact factor: 1.961
Authors: Alex C Spyropoulos; Joanna B Eldredge; Lalitha N Anand; Meng Zhang; Michael Qiu; Soheila Nourabadi; David J Rosenberg Journal: Oncologist Date: 2020-02-04